James E. Bradner, M.D.
Executive Vice President, Research and Development, Artificial Intelligence and Data
2023 – Present
3 years (current)
Legacy
Bradner, a physician-scientist who spent a decade on the Harvard Medical School faculty at Dana-Farber Cancer Institute, later led the Novartis Institutes for BioMedical Research as its president from 2016 to 2022, overseeing a unit that advanced 80 development candidates and filed 75 investigational new drug applications during his tenure. He joined Amgen in 2023 to apply AI and data science across drug discovery and development, and took on additional oversight of core R&D functions in 2026 following David Reese's retirement. He also holds an academic reputation as a co-inventor of BET bromodomain inhibitor technology used in cancer drug discovery.